Oshih Kit
Product Images NDC 59651-504

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oshih (NDC 59651-504). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. (Norethindrone Fig1)

A forest plot chart titled 'Relevant Studies of Risk of Breast Cancer with Combined Oral Contraceptives.' It compares effect estimates of breast cancer risk from various studies between ever or current combined oral contraceptive (COC) users and never users. The chart plots odds ratios (OR), relative risks (RR), and hazard ratios (HR) with confidence intervals, showing data points for multiple studies on the horizontal axis representing effect estimates from -1.5 to 2.0.*

FDA Label Image

Figure 2 (Norethindrone Fig2)

A line graph depicting norethindrone concentration (pg/mL) over time (hours), showing a peak concentration near the start and a gradual decline to near zero by 36 hours, including error bars at each data point.*

FDA Label Image

Figure 3 (Norethindrone Fig3)

A pharmacokinetic curve showing the concentration of ethinyl estradiol (pg/mL) in the blood plasma over time (hours) up to 36 hours. The graph includes data points with error bars depicting variability around the mean concentrations at each time interval.*

FDA Label Image

Figure 4 (Norethindrone Fig4)

An illustration depicting types of birth control methods organized by pregnancy rates per 100 women per year, arranged with fewer pregnancies at the top and more pregnancies at the bottom. Methods include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, behavioral methods like abstinence during fertile days, spermicide, withdrawal, and absence of birth control.*

FDA Label Image

Figure (Norethindrone Fig5)

An instructional diagram showing the weekly layout and pill-taking directions for the OSHIH kit containing norethindrone acetate, ethinyl estradiol, and ferrous fumarate tablets. It depicts four weeks, with weekly rows labeled as 'active' or 'inactive,' guidance for starting days, and arrows indicating the direction to take pills each week from left to right.*

FDA Label Image

Package Label-principal Display Panel (1 mg/20 mcg and 75 mg Pouch Label)

Packaging label for OSHIH kit containing norethindrone acetate and ethinyl estradiol and ferrous fumarate tablets, USP 1 mg/20 mcg. The label indicates 24 days of active therapy with white to off-white tablets containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, and brown tablets containing ferrous fumarate 75 mg. Mint flavor is noted. Labeler is Aurobindo Pharma Limited. The package contains one blister card of 28 tablets.*

FDA Label Image

Package Label-principal Display Panel (1 mg/20 mcg and 75 mg Pouch Blister Carton Label)

Packaging label for Oshih kit containing norethindrone acetate and ethinyl estradiol and ferrous fumarate tablets, USP 1 mg/20 mcg, mint flavor. The carton states it contains 3 pouches with 1 blister card of 28 tablets each, providing 24 days of active therapy. Distributed by Aurobindo Pharma USA, Inc., the label includes dosage and safety information, storage instructions, and regulatory contact details.*

FDA Label Image

Structure1 (Norethindrone Str1)

Chemical structure of the active ingredient norethindrone acetate and ethinyl estradiol and ferrous fumarate as shown in the image. The structure depicts a steroidal framework with hydroxyl groups and an alkyne moiety.*

FDA Label Image

Structure2 (Norethindrone Str2)

Chemical structure diagram depicting the steroidal framework with characteristic rings and functional groups, consistent with a component of the active ingredients in OSHIH. The structure includes multiple chiral centers, double bonds, and acetyl and ethynyl functional groups indicative of a synthetic progestin or estrogen derivative.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.